A Service For Professionals Wednesday, October 18, 2017
Contact (202) 540-8337
Company News Today
A Service For Professionals Wednesday, October 18, 2017 11614 Sources 410,330,017 Articles 3,134,516 Readers
Contact (202) 540-8337

Eagle Named To Cadence Pharmaceuticals Board

March 30, 2010 (FinancialWire) — Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) has appointed Michael L. Eagle to the company's board of directors.

Eagle served as vice president of Manufacturing for Eli Lilly from 1994 through 2001 and held a number of executive management positions with Eli Lilly and its subsidiaries throughout his career.

Since retiring from Lilly, he has served as a founding member of Barnard Life Sciences. Eagle currently serves on the boards of directors of Somaxon Pharmaceuticals, Micrus Endovascular and Cardio Polymers. He serves on the board of Trustees of the La Jolla Playhouse and Futures for Children.

California-based Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Powered by EIN Presswire